Proton pump inhibitor. This product is a fat-soluble weakly alkaline drug that is easily concentrated in an acidic environment. Therefore, after oral administration, it can be specifically distributed in the secretory tubules of the gastric mucosal parietal cells, and converted into the active form of sulfenamide in this high-acid environment. Then, it irreversibly combines with the sulfhydryl group of the H, K-ATPase (also known as the proton pump) in the secretory membrane of the parietal cells through a disulfide bond to form a complex of sulfenamide and the proton pump, thereby inhibiting the activity of the enzyme and blocking the final step of gastric acid secretion. Therefore, this product has a strong and lasting inhibitory effect on gastric acid secretion caused by various reasons.

Extract from the above information

Relaxes vascular smooth muscle, activates guanylate cyclase by releasing nitric oxide (NO), increases cyclic guanosine monophosphate (cGMP) in smooth muscle cells, thereby dilating peripheral arteries and veins, reducing myocardial oxygen consumption and increasing coronary perfusion.

It kills bacteria, fungi and trichomonas through strong acid and protein coagulation, selectively causes necrotic or diseased tissue and columnar epithelial protein denaturation, causes vasoconstriction and plasma protein coagulation to stop bleeding. It has a broad-spectrum antibacterial effect, including common Gram-positive bacteria, Gram-negative bacteria, fungi and certain viruses. It is particularly sensitive to Gardnerella Vaginatis, anaerobic bacteria Trichomonas and Candida, but has little effect on Doderlein Vaginalflore (vaginal lactobacillus flora). It has a selective coagulation effect on necrotic or diseased tissue, can promote tissue regeneration and epithelial re-covering, healthy spherical epithelium is not affected, and columnar epithelium may swell and shrink after contact. Topical application is non-toxic.

Epirubicin is an anthracycline cytotoxic drug, whose planar ring is embedded between base pairs and binds to DNA to form a complex, thereby inhibiting the synthesis of nucleic acids (DNA and RNA) and proteins. It can also trigger topoisomerase II to cleave DNA, produce cytocidal effects, inhibit the activity of DNA helicase, prevent enzyme-induced DNA double-stranded unwinding, interfere with replication and transcription, and participate in oxidation/reduction reactions by producing cytotoxic free radicals. Epirubicin has in vitro cytotoxic effects on a variety of mouse and human cell lines and primary cultures of human tumors, and has in vivo anti-tumor effects on mouse tumors and human cancer xenografts (including breast cancer) in athymic mice.